Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 1
1994 2
1995 1
1997 2
1998 2
1999 3
2000 6
2001 5
2002 4
2003 8
2004 10
2005 15
2006 14
2007 4
2008 8
2009 11
2010 19
2011 14
2012 19
2013 21
2014 24
2015 20
2016 24
2017 24
2018 25
2019 19
2020 29
2021 28
2022 26
2023 13
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: harigae h. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Free article. Clinical Trial.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Bishop MR, et al. Among authors: harigae h. N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904798 Clinical Trial.
[Overview].
Harigae H. Harigae H. Rinsho Ketsueki. 2023;64(6):465. doi: 10.11406/rinketsu.64.465. Rinsho Ketsueki. 2023. PMID: 37407468 Japanese. No abstract available.
[Overview].
Harigae H. Harigae H. Rinsho Ketsueki. 2016 Feb;57(2):90. doi: 10.11406/rinketsu.57.90. Rinsho Ketsueki. 2016. PMID: 26935623 Japanese. No abstract available.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: harigae h. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free PMC article. Clinical Trial.
Pyridoxine: beyond a cofactor of ALAS.
Fujiwara T, Harigae H. Fujiwara T, et al. Among authors: harigae h. Blood. 2024 Sep 26;144(13):1358-1359. doi: 10.1182/blood.2024025575. Blood. 2024. PMID: 39325482 No abstract available.
Iron metabolism and related diseases: an overview.
Harigae H. Harigae H. Int J Hematol. 2018 Jan;107(1):5-6. doi: 10.1007/s12185-017-2384-0. Epub 2017 Dec 5. Int J Hematol. 2018. PMID: 29209948 No abstract available.
The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.
Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Kameda K, et al. Among authors: harigae h. Blood. 2023 Jul 27;142(4):352-364. doi: 10.1182/blood.2022018597. Blood. 2023. PMID: 37146246 Free article.
[Academia-Industry Alliance: Recent Trend].
Nakagawa A, Perl L, Lee J, Harada-Shoji N, Ota C, Shiga T, Sunami S, Niizuma K, Endo H, Harigae H, Tominaga T. Nakagawa A, et al. Among authors: harigae h. No Shinkei Geka. 2024 Jan;52(1):213-225. doi: 10.11477/mf.1436204899. No Shinkei Geka. 2024. PMID: 38246689 Japanese.
359 results